Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults with HIV (INSTINCT/GESIDA10918 Study)

Journal:

Clinical Infectious Diseases

Published:

2025-10-10

DOI:

10.1093/cid/ciaf565

Affiliations:

23

Authors:

22

Go to article

Institutions	Authors	Share
Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Spain	4.000000	0.18
Biomedical Research Networking Center for Infectious Diseases (CIBERINFEC), Spain	3.333333	0.15
Hospital Universitario Fundación Jiménez Díaz (FJD), UAM, Spain	1.500000	0.07
Prince of Asturias University Hospital, Spain	1.000000	0.05
Hospital Universitario de Guadalajara (HUGU), Spain	1.000000	0.05
Hospital Clínico Universitario Lozano Blesa, Spain	1.000000	0.05
Health Research Institute of San Carlos (IdISSC), Spain	1.000000	0.05
Hospital Universitario Puerta de Hierro Majadahonda, UAM, Spain	1.000000	0.05
Hospital Universitario Reina Sofía, Spain	1.000000	0.05
La Fe University Hospital, Spain	1.000000	0.05
Hospital Universitario Infanta Leonor, Spain	1.000000	0.05
Vall d'Hebron University Hospital (HUVH), ICS, Spain	1.000000	0.05
Bellvitge University Hospital (HUB), ICS, Spain	0.500000	0.02
Virgen del Rocío University Hospital, Spain	0.500000	0.02
La Paz University Hospital, UAM, Spain	0.500000	0.02
Institute of Biomedical Research in Malaga (IBIMA), Spain	0.500000	0.02
Andalusian Centre for Nanomedicine and Biotechnology (BIONAND), Spain	0.500000	0.02
Center for Biomedical Research of La Rioja (CIBIR), Spain	0.500000	0.02
Hospital San Pedro, Spain	0.500000	0.02
Hospital Universitario Virgen de las Nieves (HUVN), Spain	0.333333	0.02
Instituto de Investigación Biosanitaria de Granada (ibs.Granada), Spain	0.333333	0.02

Interested in Clinical Sciences?